Fig. 1From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsThe lung metastasis changes in patients of alveolar soft tissue sarcoma with lung metastasis during treatment. a Before treatment. b Treatment after 2 cycles (42 days). c Treatment after 3 yearsBack to article page